GH Research PLC (NASDAQ:GHRS) Given Average Recommendation of "Moderate Buy" by Analysts

Key Points

• GH Research PLC (NASDAQ:GHRS) has received an average analyst rating of "Moderate Buy", with seven out of eight analysts giving a buy recommendation.
• The company's stock has a current price target of $32.00 among brokerages, with its shares recently trading at around $13.84.
• GH Research reported earnings of ($0.15) per share for the last quarter, surpassing analysts' expectations, and is involved in developing treatments for psychiatric disorders.

Shares of GH Research PLC (NASDAQ:GHRS - Get Free Report) have received an average recommendation of "Moderate Buy" from the eight ratings firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $32.00.

Several equities research analysts recently commented on GHRS shares. Wall Street Zen upgraded shares of GH Research from a "sell" rating to a "hold" rating in a research report on Saturday, July 5th. Guggenheim decreased their price objective on shares of GH Research from $32.00 to $29.00 and set a "buy" rating on the stock in a research report on Friday, May 9th. JMP Securities reiterated a "market outperform" rating and issued a $39.00 price objective on shares of GH Research in a research report on Tuesday, June 24th. HC Wainwright reiterated a "buy" rating and issued a $40.00 price objective on shares of GH Research in a research report on Friday, May 9th. Finally, Cantor Fitzgerald started coverage on shares of GH Research in a research report on Wednesday, June 4th. They issued an "overweight" rating and a $25.00 price objective on the stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets raised its stake in GH Research by 165.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company's stock valued at $207,000 after purchasing an additional 10,600 shares during the last quarter. HighVista Strategies LLC acquired a new position in GH Research in the 2nd quarter valued at about $637,000. Stempoint Capital LP acquired a new position in GH Research in the 2nd quarter valued at about $1,229,000. Virtus Investment Advisers LLC acquired a new position in GH Research in the 2nd quarter valued at about $89,000. Finally, JPMorgan Chase & Co. acquired a new position in GH Research in the 2nd quarter valued at about $79,000. Institutional investors and hedge funds own 56.90% of the company's stock.

GH Research Price Performance

Shares of NASDAQ GHRS traded up $0.09 during trading on Friday, hitting $14.02. 148,721 shares of the company were exchanged, compared to its average volume of 239,576. The company has a market cap of $729.46 million, a price-to-earnings ratio of -18.95 and a beta of 0.97. GH Research has a 1 year low of $6.00 and a 1 year high of $20.50. The firm's fifty day moving average price is $14.12 and its 200 day moving average price is $12.12.

GH Research (NASDAQ:GHRS - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.07. On average, research analysts forecast that GH Research will post -0.8 earnings per share for the current year.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).